Health Trials

Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System

The objective of this study is to demonstrate the safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA) Cardiac Catheter Ablation System in treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF).

Participants needed: 215
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Pulse Biosciences, Inc.Updated: May 6, 2026Locations: 1
Eligibility criteria

Age 18 through 85 years old (or older than 18 if required by local law) [+3]

Left atrial diameter ≥5.5 cm (anteroposterior) [+35]

Read more
Status: Recruiting

CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation

The objective of this study is to demonstrate initial safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA or nano-PFA) 360 Catheter Endocardial Ablation System in treating subjects with atrial fibrillation.

Participants needed: 60
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Pulse Biosciences, Inc.Updated: May 5, 2026Locations: 3
Eligibility criteria

Subject must be ≥ 18 and ≤ 75 years of age on the day of enrollment [+6]

Subject has an implantable electronic medical device. (i.e., pacemaker, ICD or C... [+31]

Read more
Status: Recruiting

Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System

The primary objective of this study is to reproduce in a multi-center study results obtained during the feasibility First-In-Human (FIH) study with Prof. Stefano Spiezia, MD (Ospedale del Mare, Naples, Italy) and to monitor additional thyroid-related symptoms and impact of patients quality of life post-ablation using a validated QoL questionnaire.

Participants needed: 100
Trial details
Age: 22-80Biological sex: AllType: InterventionalSponsor: Pulse Biosciences, Inc.Updated: Apr 15, 2026Locations: 3
Eligibility criteria

Participant is willing and able to provide voluntary, written informed consent t... [+10]

Participant has an implantable electronic medical device. (i.e., pacemaker, impl... [+15]

Read more
Status: Recruiting

CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation

The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.

Participants needed: 135
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Pulse Biosciences, Inc.Updated: Jan 12, 2026Locations: 2
Eligibility criteria

Subject must be between 18 and 85 years of age [+6]

Subject has an implantable electronic medical device. (i.e., pacemaker, implanta... [+34]

Read more
Status: Recruiting

CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation

This feasibility study will be conducted to demonstrate the initial safety and effectiveness of the CellFX® nsPFA™ Cardiac Clamp in performing a box lesion around the 4 pulmonary veins as an isolated procedure or as a part of a more extensive surgical ablation set in conjunction with concomitant cardiac surgical procedure.

Participants needed: 30
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Pulse Biosciences, Inc.Updated: Jan 12, 2026Locations: 6
Eligibility criteria

Subject must be between 18 and 85 years of age [+5]

Subject has an implantable electronic medical device. (i.e., pacemaker, ICD or C... [+29]

Read more